Human Models of Selective Insulin Resistance: Alpelisib, Part I

The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin. Researchers will compare the impact of single doses of both alpelisib and placebo (inert non-drug) in random order (like flipping a coin) in study participants. Participants will be asked to stay twice overnight in the hospital, take single doses of alpelisib and placebo (one or the other on each of the two hospital stays), and receive intravenous (into the vein) infusions of non-radioactive "tracer" molecules that allow researchers to measure the production of glucose (sugar) and fats by the liver. Measurements will be done both overnight, while participants are asleep and fasting (not eating or drinking other than water) and while consuming a standardized diet of nutritional beverages during the following day.

The objective is to evaluate the effect of lowering insulin levels, while maintaining constant mild hyperglycemia, on plasma glucose and lipid levels.

Study Overview

• Status: Recruiting
• Conditions: Insulin Resistance; Prediabetic State; Overweight and Obesity; Non-Alcoholic Fatty Liver Disease
• Intervention / Treatment: Drug: Alpelisib 300 mg; Drug: Placebo; Drug: [1-13C] sodium acetate; Drug: [6,6-2H2] D-glucose; Dietary supplement: Nestlé BOOST Plus

Detailed Description

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an under-appreciated complication of lipid dysmetabolism in type 2 diabetes (T2DM). Although it appears that insulin resistance (IR) is a mechanism common to both, the mechanisms linking IR to unhealthy fat accumulation in liver remains unclear. "Pure" IR would be expected to disinhibit hepatic glucose production while dampening hepatic triglyceride (TG) biosynthesis, but the excessive hepatic de novo lipogenesis (DNL) of IR-associated MASLD suggests that hepatic IR is "selective." However, the concept of IR selectivity is controversial, and because of clinical heterogeneity, lead-time discrepancies, co-morbidities, and medication effects, parsing out this pathophysiologic conundrum in humans is challenging. The investigators plan to test whether the multifactorial IR in patients at risk of T2DM/MASLD is selective by determining if inducing a discrete, "pure" form of IR, via pharmacologic inhibition of phosphoinositide-3-kinase (PI3K) with alpelisib, versus placebo, attenuates excessive DNL. Investigators will also study this question in healthy, insulin-sensitive (IS) volunteers.

Participants in this randomized crossover trial will be admitted twice to the inpatient clinical research unit. During each admission, they will take a dose of either alpelisib or placebo (in randomized order) in the evening and receive infusions of [13C] sodium acetate and [2H] D-glucose to measure DNL and endogenous glucose production (EGP), respectively, during an overnight fast. DNL measurement will then continue during the following day during 8 hours of standardized mixed-meal feedings. Blood will be drawn at defined intervals for determining levels of glucose, insulin, lipids including triglycerides and free fatty acids, and tracer/tracee enrichments for the stable-isotope tracers. There will be a 2-8-week hiatus for drug washout between the two inpatient study admissions.

• Study Type: Interventional
• Enrollment (Estimated): 32
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Joshua R Cook, MD, PhD; Phone Number: 2123056289; Email: jrc2175@cumc.columbia.edu
• Study Contact Backup: Name: Ishwari Nagnur; Phone Number: 2123059336; Email: imn2113@cumc.columbia.edu

Study Locations

• United States
  • New York
    • New York, New York, United States, 10032
      • Recruiting
      • Columbia University Irving Medical Center
      • Contact: Joshua R Cook, MD, PhD; Phone Number: 212-305-6289; Email: jrc2175@cumc.columbia.edu
      • Principal Investigator: Joshua R Cook, MD, PhD
      • Sub-Investigator: Julia J Wattacheril, MD
      • Sub-Investigator: Blandine Laferrère, MD, PhD
      • Sub-Investigator: Henry N Ginsberg, MD
      • Contact: Ishwari Nagnur; Phone Number: 2123059336; Email: zds2120@cumc.columbia.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Adults aged 18-70 years
2. Able to understand written and spoken English and/or Spanish

3. Body mass index of:

   • For Group IS: BMI 18-25 kg/m2
   • For Group IR: BMI 30-45 kg/m2

4. Evidence of insulin sensitivity or insulin resistance:

   • Insulin sensitive (for Group IS) defined as all of the following: (1) Fasting serum insulin ≤ 10 µIU/mL, (2) Absence of dysglycemia (fasting plasma glucose < 100 mg/dL and hemoglobin A1c < 5.7%), (3) Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score < 2.5, and (4) Fibrosis-4 (FIB-4) score < 1.3
   • Insulin resistant (for Group IR) defined as fasting serum insulin ≥ 13 µIU/mL plus at least one of the following: (1) Presence of prediabetic state (fasting plasma glucose 100-125 mg/dL and/or hemoglobin A1c 5.7-6.4%), and/or HOMA-IR ≥ 2.5

Exclusion Criteria:

1. Inability to provide informed consent in English or Spanish

2. Concerns arising at screening visit:

   • Abnormal vital signs: (1) Systolic blood pressure < 90 mm Hg or > 160 mm Hg and/or (2) Diastolic blood pressure < 55 mm Hg or > 100 mm Hg and/or (3) Abnormal resting heart rate < 55 bpm (except at PI's discretion) or ≥ 110 bpm
   • Abnormal screening serum electrolytes judged by the PI to be potentially clinically significant, including liver function abnormalities (either of the following): (1) Transaminases (AST or ALT) > 3.0 x the upper limit of normal and/or (2) Total bilirubin > 1.25 x the upper limit of normal
   • Laboratory evidence of diabetes mellitus: (1) Hemoglobin A1c ≥ 6.5%, and/or (2) Fasting plasma glucose ≥ 126 mg/dL
3. Reproductive concerns i. Positive qualitative β-hCG (i.e., pregnancy test) in women of childbearing potential ii. Women currently pregnant iii. Women currently breastfeeding

4. Concerns related to glucose metabolism

   • History of having met any of the American Diabetes Association's definitions of diabetes mellitus (i.e., overt diabetes)
   • History of gestational diabetes mellitus within the previous 5 years
   • Use of most antidiabetic medications (other than metformin) within the 90 days prior to screening: thiazolidinediones, sulfonylureas, meglitinides, dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, amylin mimetics, acarbose, insulin iv. Clinical concern for absolute insulin deficiency (e.g., type 1 diabetes, pancreatic disease)

5. Concerns related to lipid metabolism

   • Known diagnoses of familial hypercholesterolemia, familial combined hyperlipidemia, or familial hyperchylomicronemia in the participant or a first-degree relative
   • Use of certain lipid-lowering drugs within 14 d prior to screening visit: fibrates (e.g., fenofibrate, gemfibrozil), prescription-strength omega-3 fatty acids (e.g., icosapent ethyl), high-dose niacin (>100 mg daily)

6. Known, documented history, at the time of screening, of any of the following medical conditions:

   • Significant cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary)
   • Severe liver disease, including advanced fibrosis (e.g., fibrosis score F3-F4 by vibration-controlled transient elastography) and cirrhosis
   • Psychiatric diseases causing functional impairment that: (1) Are or have been decompensated within 1 year of screening, and/or (2) Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain/metabolic dysfunction (e.g., clozapine, olanzapine)
   • Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation
   • Bleeding disorders, including due to anticoagulation, or significant anemia (see above)
   • Active malignancy, or hormonally active benign neoplasm, except allowances for non-melanoma skin cancer and differentiated thyroid cancer (Stage I only)
7. Clinical concern for increased risk of volume overload, including due to medications and/or heart/liver/kidney problems, as listed above
8. Use of oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted

9. History of certain weight-loss (bariatric) surgery, including:

   • Roux-en-Y gastric bypass
   • Biliopancreatic diversion
   • Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months
10. Clinical concern for alcohol overuse based on chart review and/or by recruit's report of more than 14 standard drinks per week for males or more than 7 standard drinks per week for females
11. Regular use of tobacco, either daily or an average of at least 1 cigarette per day, and/or nicotine vaping more than 1 day per week
12. Clinical concern for use of illicit drugs other than marijuana or lawfully prescribed medications based on recruit's report, chart review, and point-of-care urine drug test at screening
13. History of or ongoing febrile illness within 30 days of screening
14. Any other disease or condition or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and/or interfere with the analysis of study data.
15. Known allergy/hypersensitivity to any component of the medicinal product formulations (including soy, cow dairy, or gluten), other biologics, venipuncture materials, plastics, adhesive or silicone, or ongoing clinically important allergy/hypersensitivity as judged by the investigator.
16. Dietary restrictions (e.g., vegan, kosher, halal) on gelatin present in overencapsulation

17. Concurrent enrollment in another clinical study of any investigational drug/biologic therapy within 6 months prior to screening or within 5 half-lives of an investigational agent or biologic, whichever is longer.

    • Prior participation in other studies led by Dr. Cook (PI) is excluded from this prohibition according to his medical/scientific judgment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Placebo then alpelisib (Insulin Sensitive group); On Study Visit 1, participants in the Insulin Sensitive (IS) group will undergo fasting and refed measurement of de novo lipogenesis (DNL) and endogenous glucose production (EGP) following a single dose of placebo. Then, 2-8 weeks later on Study Visit 2, participants will undergo measurement of DNL and EGP after a single dose of alpelisib 300 mg.	Drug: Alpelisib 300 mg; All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.; Other Names: Piqray; Drug: Placebo; All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.; Other Names: Placebo capsules; Drug: [1-13C] sodium acetate; All participants will receive continuous infusions of [1-13C] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental); Other Names: C13A; Drug: [6,6-2H2] D-glucose; All participants will receive continuous infusions of [6,6-2H2] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental); Other Names: D2-glucose; D2G; Dietary supplement: Nestlé BOOST Plus; All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental); Other Names: Boost drink
Experimental: Alpelisib then placebo (Insulin Sensitive group); On Study Visit 1, participants in the Insulin Sensitive (IS) group will undergo fasting and refed measurement of de novo lipogenesis (DNL) and endogenous glucose production (EGP) following a single dose of alpelisib 300 mg. Then, 2-8 weeks later on Study Visit 2, participants will undergo measurement of DNL and EGP after a single dose of placebo.	Drug: Alpelisib 300 mg; All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.; Other Names: Piqray; Drug: Placebo; All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.; Other Names: Placebo capsules; Drug: [1-13C] sodium acetate; All participants will receive continuous infusions of [1-13C] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental); Other Names: C13A; Drug: [6,6-2H2] D-glucose; All participants will receive continuous infusions of [6,6-2H2] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental); Other Names: D2-glucose; D2G; Dietary supplement: Nestlé BOOST Plus; All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental); Other Names: Boost drink
Experimental: Placebo then alpelisib (Insulin Resistant group); On Study Visit 1, participants in the Insulin Resistant (IR) group will undergo fasting and refed measurement of de novo lipogenesis (DNL) and endogenous glucose production (EGP) following a single dose of placebo. Then, 2-8 weeks later on Study Visit 2, participants will undergo measurement of DNL and EGP after a single dose of alpelisib 300 mg.	Drug: Alpelisib 300 mg; All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.; Other Names: Piqray; Drug: Placebo; All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.; Other Names: Placebo capsules; Drug: [1-13C] sodium acetate; All participants will receive continuous infusions of [1-13C] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental); Other Names: C13A; Drug: [6,6-2H2] D-glucose; All participants will receive continuous infusions of [6,6-2H2] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental); Other Names: D2-glucose; D2G; Dietary supplement: Nestlé BOOST Plus; All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental); Other Names: Boost drink
Experimental: Alpelisib then placebo (Insulin Resistant group); On Study Visit 1, participants in the Insulin Resistant (IR) group will undergo fasting and refed measurement of de novo lipogenesis (DNL) and endogenous glucose production (EGP) following a single dose of alpelisib 300 mg. Then, 2-8 weeks later on Study Visit 2, participants will undergo measurement of DNL and EGP after a single dose of placebo.	Drug: Alpelisib 300 mg; All participants will ingest one dose of alpelisib 300 mg (2 x 150-mg overencapsulated tablets) on one of two study admissions.; Other Names: Piqray; Drug: Placebo; All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.; Other Names: Placebo capsules; Drug: [1-13C] sodium acetate; All participants will receive continuous infusions of [1-13C] sodium acetate for up to 23 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental); Other Names: C13A; Drug: [6,6-2H2] D-glucose; All participants will receive continuous infusions of [6,6-2H2] D-glucose for up to 15 hours on both study visits in order to quantify de novo lipogenesis (DNL). (non-experimental); Other Names: D2-glucose; D2G; Dietary supplement: Nestlé BOOST Plus; All participants will ingest standardized mixed meals of Nestlé BOOST Plus on Study Day 1 and then smaller portions hourly x 8 hours on Study Day 2 of each study visit. (non-experimental); Other Names: Boost drink

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hepatic de novo lipogenesis (DNL) (absolute value)	Percent incorporation of newly synthesized fatty acids into plasma or VLDL TG. During both inpatient (overnight) study visits, starting after investigational agent dose. units: %	Up to 24 hours after dosing
Hepatic de novo lipogenesis (DNL) (relative value)	Percent incorporation of newly synthesized fatty acids into plasma or VLDL TG. During both inpatient (overnight) study visits, starting after investigational agent dose. unit: fold difference and/or ∆% versus other group	Up to 24 hours after dosing
Endogenous glucose production (EGP) (absolute value)	Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: mg/kg/min	Up to 15 hours after dosing
Endogenous glucose production (EGP) (relative value)	Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: fold difference and/or ∆% versus other group	Up to 15 hours after dosing

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum insulin level	Serum insulin levels in response to placebo vs alpelisib following an overnight fast and then hourly during refeeding. During Study Day 2 of both study visits, starting after investigational agent dose. units: µIU/mL	Approximately 11-19 hours after dosing
Plasma glucose level	Plasma glucose levels in response to placebo vs alpelisib following an overnight fast and then hourly during refeeding. During Study Day 2 of both study visits, starting after investigational agent dose. units: mg/dL	Approximately 11-19 hours after dosing
Triglycerides level	(Serum or plasma) triglyceride levels in response to placebo vs alpelisib following an overnight fast and then hourly during refeeding. During Study Day 2 of both study visits, starting after investigational agent dose. units: mg/dL	Approximately 11-19 hours after dosing
Free fatty acids level	(Serum or plasma) triglyceride levels in response to placebo vs alpelisib following an overnight fast and then periodically during refeeding. During Study Day 2 of both study visits, starting after investigational agent dose. units: mmol/L	Approximately 11-19 hours after dosing
Glucose kinetics: rate of appearance (absolute value)	Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: mg/kg/min	Up to 15 hours after dosing
Glucose kinetics: rate of appearance (relative value)	Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: fold difference and/or ∆% versus other group	Up to 15 hours after dosing
Glucose kinetics: rate of disappearance (absolute value)	Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: mg/kg/min	Up to 15 hours after dosing
Glucose kinetics: rate of disappearance (relative value)	Calculated from D2G tracer enrichment by the Steele equations. During both inpatient (overnight) study visits, starting after investigational agent dose. units: fold difference and/or ∆% versus other group	Up to 15 hours after dosing

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Apolipoprotein B level	(Serum or plasma) apolipoprotein B levels in response to placebo vs alpelisib following an overnight fast and then periodically during refeeding. During Study Day 2 of both study visits, starting after investigational agent dose. units: mg/dL	Approximately 11-19 hours after dosing

Collaborators and Investigators

• Sponsor: Columbia University
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of California, Berkeley; Stanford University
• Investigators: Principal Investigator: Joshua R Cook, MD, PhD, Columbia University

Study record dates

Study Major Dates

• Study Start (Actual): April 24, 2024
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: April 3, 2024
• First Submitted That Met QC Criteria: April 3, 2024
• First Posted (Actual): April 9, 2024

Study Record Updates

• Last Update Posted (Actual): April 9, 2026
• Last Update Submitted That Met QC Criteria: April 6, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Insulin resistance; Hepatic steatosis; Hyperinsulinemia; Non-Alcoholic Fatty Liver Disease; De novo lipogenesis; Glucose production
• Additional Relevant MeSH Terms: Endocrine System Diseases; Nutrition Disorders; Metabolic Diseases; Overnutrition; Body Weight; Digestive System Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Liver Diseases; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Overweight; Obesity; Fatty Liver; Non-alcoholic Fatty Liver Disease; Insulin Resistance; Prediabetic State; Hyperinsulinism; Organic Chemicals; Carbohydrates; Acids, Acyclic; Carboxylic Acids; Sugars; Acetates; Hexoses; Monosaccharides; Acetic Acid; Alpelisib; Glucose; Sodium Acetate; delta inulin
• Other Study ID Numbers: AAAU9636; K12DK133995 (U.S. NIH Grant/Contract); K23DK140614 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No